Key Stats for Thermo Fisher Scientific Stock
- 52-Week Range: $398.08 to $643.99
- Current Price: $469.35
- Street Mean Target: $599.19
- TIKR Model Target (2030, Mid): ~$722
- Q1 2026 Revenue: $11.01B (+6% YoY)
- Q1 2026 GAAP Diluted EPS: $4.43 (+11% YoY)
- FY2026 Revenue Guidance: $47.3B to $48.1B
- LTM EBIT Margin: 18.8%
Most investors never know if a stock is truly undervalued or overpriced. TIKR’s professional-grade valuation tools give you a clear, data-backed answer across 60,000+ stocks for free →
Funding Cuts, China Softness, and Tariff Headwinds on a Business That Beat Estimates Anyway
Thermo Fisher Scientific (TMO) is one of the most durable businesses in life sciences. It is also down 27% from its highs, trading at a level the stock has not seen since 2022, and the market is asking a simple question: how long does the funding headwind last?
The pressure is real, as US academic research budgets have tightened, China’s demand remains soft, and tariffs added 80 basis points of headwind to operating margins in Q1 2026. These are not trivial forces for a company that sells instruments, reagents, and services to universities, government labs, and pharmaceutical companies. When those customers pull back, Thermo Fisher feels it.
What the stock price does not fully reflect is that the company beat estimates in Q1 anyway. Revenue grew 6% to $11.01 billion. GAAP diluted EPS grew 11% to $4.43. Management raised full-year guidance to $47.3 billion to $48.1 billion and lifted the EPS outlook.
CEO Marc Casper repurchased $3.0 billion of stock and raised the dividend 10% in the same quarter. This is not a company in distress. It is a company navigating a soft cycle from a position of strength.
See analysts’ growth forecasts and price targets for Thermo Fisher stock (It’s free!) >>>
A 31% Max Drawdown While EPS Grew 11% and Guidance Was Raised
The drawdowns chart shows a stock that held up well through most of 2025, then fell sharply and continuously from February 2026 onward. The max drawdown hit 31% on May 15. The stock has partially recovered but remains 27% off its highs.
The selloff started with a January guidance miss relative to elevated Street expectations, then compounded on tariff fears and sector-wide pressure on life sciences names.
By the time Q1 results came in ahead of estimates in April, the stock had already priced in a significantly worse outcome. The gap between the operating results and the stock price is what makes the setup interesting.
See how Thermo Fisher performs against its peers in TIKR (It’s free!) >>>
EPS Flat for Three Years, Consensus Expecting a Step-Change Higher From 2026 Onward
The EPS chart captures the full arc, as EPS peaked at $25.13 in 2021 during the COVID diagnostics boom, then declined as that tailwind reversed. By 2023, it had compressed to $21.55 and essentially flatlined through 2024 and 2025 as the biotech funding cycle softened and China weakened.
The consensus is forecasting a break from that pattern starting in 2026. Street estimates call for around $25 this year, climbing toward $27 in 2027 and approaching $38 by 2030. The thesis is that the current funding headwinds are cyclical rather than structural, and that Thermo Fisher’s product portfolio and manufacturing scale position it to capture an outsized share of demand when research budgets recover.
Thermo Fisher serves customers across four segments, the largest of which is Laboratory Products and Biopharma Services, which generated $6.04 billion in Q1 2026 revenue. No single segment dominates the story, which is part of what makes the business resilient across cycles.
The Clario acquisition, which closed during Q1, adds clinical data capabilities that deepen the company’s position with pharma and biotech customers running drug development programs.
See historical and forward estimates for Thermo Fisher stock (It’s free!) >>>
A ~$722 Mid-Case Target, About 10% Annualized, and a Street Mean at $599
The TIKR valuation model targets around $722 per share for Thermo Fisher by year-end 2030, implying roughly 54% total return from the current price of $469.35, or about 10% annualized. The mid-case assumes around 4% to 5% annual revenue growth and net income margins near 21%, reflecting gradual normalization of the research funding environment rather than a sharp recovery.
The high case implies a target near $1,108 and total returns above 135%. The Street mean of $599 implies about 28% upside from current levels, reflecting more conservative near-term assumptions on the pace of demand recovery.
The bull case is that the EPS trough is behind the company, Clario adds a durable new revenue stream, and a stock at roughly 19 times forward earnings is a historically attractive entry point for one of the best compounders in healthcare.
The bear case is that academic and government funding cuts persist longer than expected, China remains a drag, and tariffs keep pressure on margins through the back half of the year.
Thermo Fisher has compounded earnings at around 10% annually over the past decade. The question is whether the current discount to its own history is a buying opportunity or a sign that the growth rate is structurally lower than it used to be.
See the exact moment Wall Street upgrades a stock before the rest of the market piles in — track analyst rating changes in real time with TIKR for free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
